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Executive Summary 
Key words: BP, bone, diffusion, 
alendronate, scaffold 
Bisphosphonates (BPs) are used to mitigate 
osteoporosis in patients who are at high risk 
for bone fractures.  Common methods of 
administration of BPs rely on systemic 
delivery, which can lead to abdominal 
discomfort and unwanted concentrations of 
drug in other areas of the body. However, 
there is a limited understanding of the 
diffusion of BPs via localized delivery from 
scaffolds. This study investigates the 
diffusion of alendronate, a commonly used 
BP, from a scaffold into bone. 
A model for diffusion with fluid flow was 
constructed using the commercially 
available computational software COMSOL.  
The femur bone is approximated as a 3D 
cylinder of length 0.1 m with four layered 
subdomains: scaffold, periosteum, compact 
bone, and marrow.  The layers are of radius 
0.0002 meters, 0.00022 meters, 0.001 
meters, and 0.0138 meters respectively.  BPs 
have a diffusion constant of 115·10-12 square 
meters per second, 2.44·10-10 square meters 
per second, 2.44·10-10 square meters per 
second, and 1·10-12 square meters per 
second respectively in the four layers of the 
domain.   The periosteum and compact bone 
have capillaries that run the length of the 
domain.  These are modeled as randomly 
distributed identical cylinders running the 
length of the domain with a unidirectional 
fluid flow of 5·10-5 meters per second with a 
fluid density of 1060 kilograms per cubic 
meter.  The initial conditions are 
concentration of 0 everywhere expect for the 
scaffold subdomain which has an initial 
concentration of 0.018 moles of alendronate 
per cubic meter of bone.  These values can 
be found in Appendix A, Table 2. 
The results of this model show the 
concentration of bound alendronate in the 
bone reaches an effective concentration of 
1·10-4 moles per cubic meter before 10 
hours.  We have also found the bound 
alendronate fraction has a low dependency 
on the initial scaffold concentration with the 
bound alendronate fraction at over 90% 
alendronate clearance time being over 0.8 
for varying initial concentrations.   
Sensitivity analysis revealed that bound 
alendronate concentration is not dependent 
on the diffusivities of compact bone or 
marrow, or on blood velocity, but is highly 
dependent on initial scaffold concentration 
and the binding rate constant of alendronate 
to bone. 
This model provides a comprehensive 
understanding of how BPs move through the 
bone and the time it takes for BP 
concentration to reach certain levels in the 
bone.  This in turn allows for more accurate 
dosage times and amounts in order to 
provide the most efficient bone loss 
prevention. 
Introduction 
Background 
Osteoporosis, the loss of bone tissue, is a 
common problem facing astronauts who 
spend long amounts of time in space.  
Sustained exposure to zero gravity has been 
known to increase calcium in the blood, 
thereby accelerating osteoclast bone 
resorption.  Osteoclast bone resorption is a 
process which has been closely linked to 
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osteoporosis and bone loss [1, 2].  In order 
to assess and ensure a person’s health during 
future long-duration spaceflight missions, a 
process will need to be developed to combat 
osteoporosis.  Ideally, such a process would 
be safe and accurate.   
There are currently methods for treating 
osteoporosis through systemic 
administration of BPs.  The drug is highly 
water soluble and has a short half-life in the 
blood [3].  Drugs such as BPs have a high 
binding affinity to hydroxyapatite and as 
such are able to target large quantities of the 
molecule found in bone [3]. Once BPs are 
taken up by osteoclasts, they are 
metabolized into varying intermediates 
which all ultimately result in apoptosis of 
osteoclasts [4].   
Oral administration in the form of a pill is 
one of the simplest and least expensive 
modes of BP delivery.  An advantage of oral 
drug delivery is its ease of administration. 
One major disadvantage is the very low 
absorption of the drug into the bloodstream 
and ultimate delivery to the bone.  
According to a recent study by Nakaya et al 
in 2016, bioavailability of BPs is 
approximated to be around 1% after 
consumption, and can be even lower if food 
is ingested with the drug [5].  In addition, 
orally administered BPs are known to cause 
gastrointestinal discomfort [5]. Studies 
involving alternative delivery methods have 
attempted to address the various problems 
associated with oral administration.  These 
alternatives include nasal sprays, 
intravenous injections, and implants [6].  A 
more recent method of drug delivery is 
through the use of a scaffold. A bio-safe 
bone cement scaffold is often used for 
localized administration of drugs.  Current 
procedures involve adding BPs to scaffold 
bone substitutes in order to target 
accelerated healing of broken bones [7].   
Previous work has attempted to characterize 
the absorption of BPs in the bloodstream.  
Such studies aim to limit the concentration 
of BPs in the blood, which can be dangerous 
at high concentrations [8].  The absorption 
and excretion of BPs in blood and urine is 
well characterized from time of ingestion to 
time of excretion [6, 8].  It has been shown 
that BPs have a high affinity for inorganic 
materials in bone [3], but research into the 
uptake process is lacking.  Previous model 
work has determined a concentration profile 
for BPs using constant variables across the 
bone [10]. 
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Problem Statement 
This study is focused on designing a more 
efficient form of local drug delivery using a 
scaffold.  The scaffold is wrapped around a 
targeted section of bone. The model uses 
alendronate, a common type of BP, and a 
femur bone with dimensions characteristic 
of an average human male [20].   
 
Initial concentrations of alendronate in the 
scaffold is increased to study the effect of 
different initial scaffold concentrations on 
bound concentrations in the bone.  This 
increase is limited to prevent a dangerous 
amount of BP from entering the blood 
stream. The main processes in this study 
included a mass transfer of drug from the 
scaffold into the bone, decay of free 
alendronate as the drug binds to bone, and 
fluid flow of blood through capillaries in the 
bone. COMSOL was used to model the 
physical phenomena and physiological 
processes that were considered relevant to 
the drug administration. 
 
Design Objectives 
This model geometry was developed to 
accommodate the following objectives: 
i. Find the time it takes to reach 
effective concentration (0.1 mM) in 
compact bone domain [9]. 
ii. Determine the time at which over 
90% of drug has either left the 
domain or is in the bound state. 
iii. Determine the bioavailability 
(fraction of initial drug bound to 
bone) due to local delivery of 
alendronate after the time derived in 
objective 2. 
The following assumptions were made in the 
design of our model in order to 
accommodate available parameters and 
implement the model into COMSOL. 
• Domain (femur shaft) is 
approximated as a cylinder  
• Domain has three distinct regions 
with uniform properties in each 
region  
• Drug only diffuses from scaffold into 
bone  
• Scaffold has uniform initial drug 
concentration of .018 mol/m3 
• Movement of BP in domain is only 
due to simple diffusion and 
convective flow  
• Losses of BP from the domain are 
only through binding and capillaries 
• Binding occurs only in the compact 
bone subdomain 
• No saturation of binding sites occurs 
• Diffusion from scaffold starts 
uniformly across scaffold at t = 0 s  
• Blood vessels are modeled as 
randomly distributed cylinders in the 
compact bone and periosteum  
• Capillaries are the only blood vessels 
present 
• Capillaries in the compact bone 
extend vertically through the full 
length of the domain  
• Loss of drug from blood vessels in 
periosteum is approximated as a 
generalized sink term   
• No blood vessels in the marrow  
Problem Schematic 
Previous work involving BP scaffolds apply 
the scaffold directly to injured bone to 
accelerate healing. This study investigates 
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the effect of wrapping a scaffold around 
healthy bone to mitigate bone loss. Figure 1 
shows a schematic of the design and the 
process of BP diffusion through the various 
layers of bone.  
 
  
Figure 1: Schematic of model shown as a cross-
section of the geometry. Capillaries in 
periosteum are much closer than capillaries in 
compact bone.   
The bone geometry was modeled as a thin 
slice of a series of cylindrical shells as 
shown in Figure 2. The separate cylindrical 
shells represent discrete layers of bone and 
are defined as follows: Scaffold is from the 
outermost shell (ro=15.22mm, ri=15.02 
mm); Periosteum was the next inner shell 
(ro=15.02mm, ri=14.8 mm); Compact bone 
was the next inner shell (ro=14.8, ri=13.8 
mm); Bone Marrow was the inner most shell 
(ro=13.8mm, ri=0 mm).  A thin slice was 
used in order to reduce the amount of 
capillaries that had to be implemented to a 
number that could be easily integrated into 
the chosen geometry.  
 
  
Figure 2: The geometry is modeled as a thin 
slice of the bone at <1° (appears as a rectangle 
in COMSOL because of the small angle). 
The model described by Figures 1 and 2 is 
used to examine BP diffusion into the bone 
tissue in the femur. This transient 3D model 
simulates diffusive mass transfer of BP from 
the scaffold to the bone layers as well as 
unidirectional convective flow through the 
capillaries. The domain of the model is the 
femoral shaft, the section of the femur with 
the distal and proximal heads removed, and 
the scaffold that is wrapped around it. All 
subdomains, with the exception or the 
capillaries, are modeled as a solid, with the 
capillaries modeled as pipes with 
unidirectional flow. As BP diffuses through 
the tissue, it is bound by the hydroxyapatite 
in the compact bone. This consumption of 
BP by the bone in turn decreases the BP 
concentration in the blood as it flows down 
the femur.   
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Methods 
Governing Equations 
Due to the different processes that are acting 
in each subdomain, each subdomain has a 
unique governing equation describing the 
free alendronate concentration associated 
with it. 
 
The compact bone subdomain was modeled 
as having transient diffusion with a first 
order reaction term that represents the 
binding of alendronate in the compact bone 
(1).  
 
This first order reaction rate was modeled by 
converting a reaction term from literature 
[24]. This term was also multiplied by a 
Boolean operator which ensures that the 
reaction only happens when the 
concentration is a real value. 
The negation of (2) was used to evaluate the 
concentration for the bound alendronate in 
the compact bone.   
 
The concentration profile of free alendronate 
in the capillaries was determined by 
considering transient diffusion with 
convection (3). The coupled convection 
physics (4) was modeled as pipe flow, as 
derived from the Navier-Stokes Equation, 
for efficient computational resource 
allocation.  
 
The concentration profile of free alendronate 
in the periosteum, scaffold, and marrow 
subdomains was determined using the 
equation for cylindrical diffusion (5) due to 
no alendronate binding or convective flow in 
these subdomains.  
Boundary and Initial Conditions  
COMSOL's outflow boundary condition was 
implemented at the bottom of the capillaries, 
while a zero-concentration boundary was 
implemented for the inflow of new blood. 
The flux value is zero along the rest of the 
outer edges of the domain. 
Table 1: Initial concentrations of free 
alendronate in the layers of the modeled 
domain 
Parameters Initial Values 
ccapillaries 0 mg/L 
ccompact  0 mg/L 
cperiosteum 0 mg/L 
cmarrow 0 mg/L 
cscaffold 0.018 mol/m
3 [26]  
            
Our model includes zero initial 
concentrations of free and bound 
alendronate. The initial concentration of free 
alendronate in the scaffold was derived from 
previous literature [26]. 
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Implementation and Mesh Design 
A 3D model was created for finite element 
analysis in COMSOL.  The geometry was 
constructed by extruding a layered wedge of 
0.5 degrees of a circle by 100 millimeters. 
This geometry was modified by the 
subtraction of several cylinders to create 
space for the capillaries. These capillaries 
were later added to the model as separate 
shapes. The material properties for the 
domain are listed in the Appendix A. The 
top of the capillaries were set to a zero 
concentration. The bottom of the capillaries 
were given an outflow condition. Following 
this, a no flux condition was implemented at 
the remaining boundaries. The initial 
concentrations are as specified in the 
previous initial concentrations section.  
A swept distribution was used to construct 
the mesh which is common practice for 
piped geometries.  Our mesh uses standard 
size parameters from the finer section as 
follows: Maximum element size 16.5 
millimeters, Minimum element size 0.001 
millimeters, Maximum element growth rate 
1.4, Curvature factor 0.4, Resolution of 
narrow regions 0.7.  
 
Figure 3: 2D view of mesh                                    
 
  
Figure 4: 3D view of mesh 
 
Results and Analysis 
Mesh Convergence 
The average bound concentration over the 
compact bone-bone marrow layer was 
measured to approximate the mesh 
convergence. Figure 5 displays the mesh 
convergence by minimum element size. The 
right plot shows the concentration at a fixed 
time of 72 hours with varied minimum 
element size.  The plot contains four data 
points. These plots show that 0.001 
millimeter minimum element size is all that 
is needed for a properly conducted 
simulation due to there being no change in 
concentration for smaller minimum element 
sizes (Fig. 5B).                                                          
 
(A) 
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(B)  
Figure 5: (A) Concentration vs. time for 
different element sizes. (B) Concentration at 
compact bone-bone marrow interface vs. 
minimum element size (72 hours).  There is no 
concentration change for minimum element size 
smaller than .001 millimeters. 
 
Fluid flow was implemented in COMSOL to 
model blood flow in the capillaries.  Figure 
6 shows a plot of the velocity field in the 
capillaries. The capillary blood flow exhibits 
laminar parabolic fluid flow. The flow was 
simplified to parabolic flow to reduce the 
computation time in COMSOL.  
 
  
Figure 6: Initial velocity field in capillaries 
 
 
The concentration of unbound BP was found 
after 72 hours.  Figure 7 displays a cross 
section of the bone model from the 
perspective of looking down into the 
capillaries. The majority of the BP appears 
to be in the bone marrow at this time. The 
capillaries carry the drug down toward the 
bottom of the domain, where it is then 
removed. 
 
  
Figure 7: 2D cross section of concentration at 
72 hours 
 
In order to see how the concentration of 
free, or unbound, alendronate changed over 
time, a plot of average free concentration vs 
time was obtained. 
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Figure 8: Average concentration of free 
alendronate in the domain over time 
Figure 8 shows the average concentration of 
free alendronate in the domain over a time 
period of 72 hours.  The concentration 
decreases rapidly until the end of the time 
period, in which it approaches zero.  The 
losses of free alendronate in the domain 
include binding to compact bone and 
removal by capillaries. 
Next, in order to determine the 
bioavailability of the drug and the severity 
of its side effects, the rate of BP exiting the 
domain was investigated.  Figure 9 displays 
the flux of drug out of the domain through 
the bottom of the capillaries.  The amount of 
unbound drug exiting the bone domain can 
be used to determine drug concentrations in 
the blood, which then can be used to 
determine if safe blood levels are exceeded.  
The outflow is used to validate the model by 
comparing the bioavailability to that of 
experimental data using similar techniques. 
 
  
Figure 9: Flux of drug out of bottom of 
capillaries vs. time 
 
The amount of drug entering blood was 
investigated in Figure 9. This was calculated 
via surface integral of the normal 
concentration multiplied by velocity over 
the bottom of each unique capillary. The 
instantaneous concentration is more 
important in determining the spread of the 
drug systemically since the half-life of BPs 
in plasma is about an hour [1]. 
Model Validation 
Our model data as well as experimental data 
were used to compare bound drug 
concentrations over time.  Figure 10 
demonstrated the similar alendronate 
binding profiles of our model compared to 
experimental data.  
8 
 
 
Figure 10: Fraction of drug bound to bone vs. 
time (From existing paper: [10]) and fraction of 
drug bound to bone vs. time from COMSOL 
values 
The top four lines represent outputs from 
our model, while the bottom three lines 
represent experimental data.  The bottom-
most line represents a BP dose high enough 
to cause acute toxicity in patients.  This 
deviation from the expected values of our 
model as a defect in our model was 
anticipated.  The highest concentration used 
in the experimental data was intended to 
show that BPs can saturate binding sites at 
high concentrations. We have excluded this 
mechanism from our model since the 
amount needed to saturate bones is greater 
than the minimum effective dose by several 
orders of magnitude. This data is derived 
from the reaction rate data from COMSOL 
in the compact bone domain.  The data is 
then averaged over a time interval and 
multiplied by that time interval. This is 
performed and summed at the specified 
points to approximate a time interval.  
Figure 10 shows that the bioavailability, or 
bound fraction of initial drug concentration, 
of alendronate at clearance time is 90%.  
This value represents a much higher 
bioavailability than the 1% associated with 
oral administration [5].  
Optimization 
The probability of bisphosphonate-related 
toxicity is low, probably because of the 
drug's rapid plasma and soft tissue clearance 
[11].  The proposed upper bound of 
alendronate concentration in the blood to 
avoid toxic levels is 10-4 M [12]. The 
proposed lower bound, or the effective 
concentration of alendronate in the bone is 
0.1 millimols [9].  Binding was previously 
demonstrated to last for very long times, 
with a half-life in bone of over 10 years 
[25].   
Our objective function: 
 
(6)  J = ΣFb(ci) + ΣFc(cj) 
Fb(ci) =  1, ci ≥ 10-4                                     
=  0, ci < 10
-4                                                           
Fc(cj) = 1000, cj  ≥ 10-1  
=  0, cj  < 10
-1 
 
This objective function is a maximization 
function whose value increases with bound 
alendronate above the effective 
concentration and decreases with free 
alendronate above the toxic concentration in 
the blood.  The first term Fb(ci) tracks the 
volume of compact bone that contains bound 
alendronate above the effective 
concentration of 10-4 moles and the second 
term Fc(cj) tracks the volume of capillary 
that contains free alendronate above the 
toxic concentration of 10-1 moles at a much 
higher weighting than Fb(ci). 
 
9 
 
 
Figure 11: Optimization function over time at 
several different values of initial concentration  
Figure 11 shows that the effective 
concentration is reached in 99% of the 
domain by volume over the time period, 
with this value reaching a steady number in 
short time. It also shows that the level of 
toxicity does not change with regard to time 
or dosage, suggesting that no tissue reaches 
the toxicity value at these concentrations.  
Sensitivity Analysis 
A sensitivity analysis was performed to 
determine the relative importance of certain 
parameters on the alendronate bound in the 
compact bone. Parametric sweeps were used 
to perform these analyses for the values 
listed in Table 4 of Appendix A. 
The sensitivity analysis in Figure 12 shows 
the percentage change of bound alendronate 
for both a 20% rise and fall of the tested 
parameter.  
 
Figure 12: Percentage change in alendronate 
concentration from varying property and 
parameter values 
The alendronate concentration over 72 hours 
was most sensitive to changes in the reaction 
rate as well as the initial scaffold 
concentration, and least sensitive to the 
changes in diffusivities in both the compact 
bone and bone marrow. These results 
demonstrate that the initial concentration of 
alendronate is significant when designing 
the scaffold. Control of the initial drug 
concentration per unit scaffold area should 
take precedence in achieving consistent 
results.     
 
Conclusions 
The work in this paper simulates the 
physiological limitations of a localized 
delivery of bisphosphonates from a scaffold. 
Our data on the concentration of drug has 
shown that the time for this drug to take 
effect is under 5 hours. Our data also shows 
that the time for clearance of unbound 
alendronate from the body is on the order of 
several days, as previously reported [10]. 
We also found the fraction of alendronate 
that binds in the compact bone, a substantial 
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factor for the bioavailability is very high 
[10]. 
More research needs to be performed in 
order to obtain accurate parameter values for 
BPs.  Many of the parameters used in this 
paper were for drug analogues or were from 
animals other than humans. Furthermore, a 
more accurate rendition of our model may 
better account for the directionality of blood 
flow in the femur and may also have a level 
of interplay and connections between blood 
vessels. The design of our scaffold, a ring 
encircling the bone, has yet to be produced 
and experimentally tested. Most current 
scaffold are designed as blocks that are 
inserted into fractures in bone, though the 
ring design has no foreseeable restrictions 
on creation and experimental 
implementation. 
 
 
 
 
 
 
 
 
Appendix A 
Parameters 
Table 2: Model Parameter Values  
Parameter Value Source 
Radial thickness of bone 
marrow (rm) 
0.0138 m  [31] 
Radial thickness of compact 
bone (rc) 
0.001 m  [30] 
Radial thickness of 
periosteum (rp) 
2.2e-4 m  [29] 
Radial thickness of scaffold 
(rs) 
200 um   [33] 
Radius of capillary (rca) 4 um [21] 
Diffusivity of compact bone 
(Dc) 
150e-12 m2/s [23] 
Diffusivity of bone marrow 
(Dm)  
1e-12 m2/s  [18] 
Diffusivity of periosteum 
(Dp) 
2.44e-10 m2/s [22] 
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Diffusivity of scaffold (Ds) 115e-12 m
2/s [15] 
Diffusivity of blood (Db) 7.8e-11 m
2/s [32] 
Density of compact bone (ρc) 1.901 g/cm3 [27] 
Density of bone marrow (ρm) 1.200 g/cm3 [27] 
Density of blood (ρb) 1060 kg/m3 [28] 
Binding rate constant (K) 90*10
-3 1/hr [24] 
Distance between capillaries 100-150 um center to center [21] 
 
Table 3: COMSOL Variables  
Variable Name Description 
velocity Velocity of blood in capillary 
min_e Minimum element size for mesh 
D_bone Diffusivity of compact bone 
C_init Initial concentration in scaffold 
 
Table 4: Sensitivity Analysis Parameters 
Parameter -20% of original value +20% of original value 
Compact Bone 
Diffusivity 
1.2e-10 m2/s 1.8e-10 m2/s 
Initial Scaffold 
Concentration 
0.0144 mol/m3 0.0216 mol/m3 
Blood Velocity 40 um/s 60 um/s 
Bone Marrow 
Diffusivity 
1.2e-12 m2/s 1.8e-10 m2/s 
 
Appendix B 
CPU Time  
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